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2,3 How can we explain this discrepancy in the literature on the use of ASCs during breast augmentation?
We encountered a similar discrepancy in the literature several years ago. One study found that recombinant tissue factor pathway inhibitor eliminated the thrombogenicity of microvascular anastomoses in the laboratory, 4 but a multicenter, prospective, double-blinded, randomized controlled clinical trial failed to demonstrate that recombinant tissue factor pathway inhibitor substantially improved free flap survival rates. 5 In a previously published article, we focused on anastomosis as the most critical requirement for free flaps survival, but eventually realized that the clinical fate of the flap was often sealed by many other factors. 6 The successful outcome of complex procedures such as large-volume fat grafting and free flap surgery depends on multiple, linked factors, and the weakest link in the series of factors determines the outcome of the procedure. In previously published research, we identified the graft as the most critical aspect of a large-volume fat grafting procedure, when, in fact, the clinical outcome of such procedures actually depends on many other limiting steps. To elaborate on these steps, we compared a surgeon performing a fat grafting procedure to a farmer planting seeds in a field. 7 The success of the procedure depends on four "S"s -the seeds (the graft), the soil (the recipient site), the sowing technique (the surgical craftsmanship), and the support (the aftercare of the graft site and the patient). Perfectly optimizing one of these factors does not compensate for another factor being suboptimal. Success depends on optimization of these four factors.
Once all factors are optimized, a specific graft-torecipient interaction has to occur in order for revascularization of the graft to occur. This interaction can be represented by the following equation: G + R = RG. In this equation, the survival of a free fat graft (G) depends on its interaction with the recipient tissue (R) to yield a revascularized, surviving graft (RG). This interaction has a specific stoichiometry. Quadrupling G or enhancing its quality without altering R will not yield better RG. We have previously showed that, in large-volume fat grafting procedures, RG augmentation is strongly correlated with the expansion of R, and enlarging R is linearly related to better RG, regardless of the number of G. 8 This suggests that, in breast augmentations, the recipient site is the limiting factor in fat graft revascularization.
Utilizing ASCs as a way of improving large-volume fat grafting is as ineffectual as adding more horsepower to a car stuck in heavy traffic. Traffic has to improve before more horsepower can make a difference. Similarly, the recipient site has to be improved before optimizing the quality or the volume of the fat graft can make a difference. Jung et al. 1 graft volumes, resulting in increased interstitial fluid pressure and decreased graft perfusion. 9 We also commend Jung et al. for reporting the percentage of augmentation of the recipient site as an outcome ( Figure 4A ). This is the most relevant measure of the success of a large-volume fat grafting procedure, rather than the most commonly reported measure of the procedure's success, the percentage of graft survival. 10 Grafting four G into one R site can, at best, result in one RG (25% graft survival and 75% necrosis). Oversupplying G beyond the available R will result in graft necrosis and will reduce graft survival without improving the final amount of successful graft revascularization. In large-volume fat grafting, in which the surgeon tries to significantly enlarge a limited recipient site, the limiting factor is the availability of R sites.
To reiterate, what matters here is the percentage of augmentation of the recipient site, not the percentage of graft survival. Assuming that the recipient sites are similar in size to the graft, and every R can be made to become RG, doubling the recipient site is the very best one could expect from fat grafting. In fact, the best-documented study of breast augmentation with fat grafts showed a 40% augmentation, 11 about the same amount of augmentation that Jung et al. achieved by utilizing ASCs during breast augmentation. The percentage of augmentation only approaches 100% when the recipient site is more than double by pre-expansion. 12 We commend Jung et al. for reporting clinical findings that seemingly contradict the accepted precepts of cellular biology; further studies in this area will ultimately enhance the clinical utility of fat grafting by forcing the scientific community to explore alternate explanations and interventions. Approaching fat grafting as a multifactorial, three-dimensional procedure will lead to more effective clinical interventions.
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